The Dutch public-private partnership, Top Institute Pharma (TI Pharma), is helping fund a project aimed at developing a vaccine for Chikungunya, an insect-borne virus that can cause disability. There is currently no vaccine available for the disease. The project has a budget of €2.3 million which will be jointly funded by TI Pharma and members of the research consortia.
